Skip to main content
Celyad Oncology SA logo

Celyad Oncology SA — Investor Relations & Filings

Ticker · CYAD ISIN · BE0974260896 LEI · 549300ORR0M8XF56OI64 BR Professional, scientific and technical activities
Open in API
Filings indexed 923 across all filing types
Latest filing 2025-09-25 Earnings Release
Country BE Belgium
Listing BR CYAD

About Celyad Oncology SA

https://celyad.com/

Celyad Oncology is a biotechnology company primarily focused on unlocking the potential of its intellectual property in the field of cell therapy. The company discovers and develops innovative technologies for Chimeric Antigen Receptor T-cell (CAR-T) therapies aimed at treating cancer. Its differentiated strategy includes the advancement of proprietary technology platforms and CAR T-cell candidates designed to broaden the range of treatable cancer indications and overcome the main limitations of existing CAR T-cell therapies.

Recent filings

Filing Released Lang Actions
PR-HY-Financial-Results-2025-FR_final.pdf
Earnings Release Classification · 100% confidence The document is an earnings release from Celyad Oncology detailing their financial results for the first half of 2025. It includes key financial highlights, a summary table of financial data, and management commentary on the results. While it mentions that the full interim report is available on their website, the document itself provides sufficient substantive financial data and analysis to qualify as an Earnings Release (ER) rather than just a report publication announcement. H1 2025
2025-09-25 French
Celyad - Financial Report H1-2025 - EN - V6.pdf
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'INTERIM FINANCIAL REPORT' for the 'First Half 2025'. It contains a comprehensive set of unaudited consolidated interim financial statements, including the statement of financial position, comprehensive income, changes in equity, and cash flows, as well as detailed management discussion and analysis (MD&A). It is not a mere announcement or certification, but the full interim report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-09-25 English
Celyad - Financial Report H1-2025 - FR - V6.pdf
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'RAPPORT FINANCIER INTERMÉDIAIRE' (Interim Financial Report) for the first half of 2025. It contains comprehensive financial statements, management discussion and analysis (MDA), and notes to the financial statements, which are characteristic of an Interim/Quarterly Report (IR). It is not an announcement of a report (RPA) as it contains the full content, nor is it a full annual report (10-K). H1 2025
2025-09-25 French
20250911_PR_Fortress Transparency Notification ENG.FINAL.pdf
Major Shareholding Notification Classification · 100% confidence The document is a formal notification regarding a change in major shareholding (transparency notification) for Celyad Oncology SA. It details the passive crossing of a 60% voting rights threshold by Fortress Investment Group LLC, as required by the Belgian Law of 2 May 2007. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2025-09-11 English
20250911_PR_Fortress Transparency Notification FR.FINAL.pdf
Major Shareholding Notification Classification · 100% confidence The document is a formal notification regarding a change in significant shareholding (transparency notification) for Celyad Oncology SA. It details the passive crossing of a 60% threshold by Fortress Investment Group LLC due to the activation of double voting rights. This type of filing is a standard regulatory requirement for disclosing major shareholding changes, which falls under the 'Major Shareholding Notification' category.
2025-09-11 French
20250904_PR_Double-voting-rights.ENG_Website.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a regulatory disclosure regarding the total number of voting rights and shares, issued in accordance with Article 15 of the Belgian Law of 2 May 2007. This type of disclosure is a standard regulatory requirement for companies listed on a regulated market to inform the public about changes in their capital structure and voting rights. It does not fit into specific categories like 'Major Shareholding Notification' (which tracks individual investors) or 'Share Issue' (which focuses on the act of issuance). Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general regulatory announcement.
2025-09-04 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.